Openbookopenbook
Equity
Daicel Corporation(DACHF)
USD --+0.00%
Reward56Moderate
Risk27Low
📊75%Data
4.7% dividend yield
DACHF
+0.0 · +0.00%
USD · PINK
Daicel Corporation | Basic Materials
Dividend King
Market Cap:2.76Bn
ℹ️
Reward Rating
56
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
27
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on DACHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Daicel Corporation?

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally.

DACHF · Verdict

Solid reward · low risk

DACHF stands out on volatility and cash flow, but watch the profitability signal.

Based on 88% data coverage

DACHF · Verdict

What’s working & what to watch

Strengths 4

  • Volatility95/100

    Top decile vs peers

  • Cash flow71/100

    4% free-cash-flow margin

  • Valuation70/100

    Above average

  • Growth66/100

    Rev +7.8% CAGR · earnings +16.5%

Watchouts 1

  • Profitability33/100

    8% net margin · 11% ROE

Model-based scoring. For information only — not financial advice.

What is Daicel Corporation?

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. The company is listed on the PINK in USA, operating in the Basic Materials sector, with a market capitalisation of 2.76B, and a P/E ratio of 12.3x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorBasic Materials
Market Cap2.76B
P/E Ratio12.2874
Dividend Yield4.72%
52 Week High8.52
52 Week Low8.43
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding258M
No. of Employees11,178
IndustrySpecialty Chemicals
ExchangePINK
Beta0.292
CurrencyUSD · Reports in JPY
Websitewww.daicel.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.